Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Junshi Signs $728 Million Deal Granting Rights for Anti-PD-1 in 21 Countries to Dr. Reddy’s

publication date: May 8, 2023

Shanghai Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to India’s Dr. Reddy’s Labs in a deal worth up to $728 million. Junshi’s toripalimab is approved for six indications in China. Dr. Reddy’s will own rights to the drug in Latin America, India and South Africa, with potential to add Australia, New Zealand and nine other countries. The company also bought an exclusive right of first negotiation for commercialization of two other Junshi products. Junshi is testing toripalimab, the first domestic anti-PD-1 mAb approved for commercialization in China, for 15 indications globally. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues: